INmune Bio Inc (INMB)
11.62
-0.22
(-1.86%)
USD |
NASDAQ |
May 01, 16:00
12.75
+1.13
(+9.72%)
After-Hours: 19:49
INmune Bio Revenue (TTM): 0.155M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.155M |
| September 30, 2023 | 0.224M |
| June 30, 2023 | 0.279M |
| March 31, 2023 | 0.249M |
| Date | Value |
|---|---|
| December 31, 2022 | 0.374M |
| September 30, 2022 | 0.44M |
| June 30, 2022 | 0.356M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.155M
Minimum
Dec 2023
0.44M
Maximum
Sep 2022
0.2967M
Average
0.279M
Median
Jun 2023
Revenue (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 2.472B |
| Sarepta Therapeutics Inc | 1.243B |
| Dare Bioscience Inc | -- |
| Zevra Therapeutics Inc | 27.46M |
| Kodiak Sciences Inc | -- |